Baillie Gifford & CO Exscientia PLC Transaction History

Baillie Gifford & CO

$126 Billion
Q1 2024

A detailed history of Baillie Gifford & CO transactions in Exscientia PLC stock. As of the latest transaction made, Baillie Gifford & CO holds 4,574,405 shares of EXAI stock, worth $23.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

4,574,405

Previous 4,690,480 2.47%

Holding current value

$23.3 Million

Previous $30.1 Million 12.97%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$5.3 - $7.51 $615,197 - $871,723	-116,075 Reduced 2.47%	4,574,405 $26.2 Million
Q4 2023 Jan 26, 2024	SELL	$4.35 - $6.88 $775,735 - $1.23 Million	-178,330 Reduced 3.66%	4,690,480 $30.1 Million
Q3 2023 Nov 13, 2023	SELL	$4.52 - $8.9 $959,858 - $1.89 Million	-212,358 Reduced 4.18%	4,868,810 $22 Million
Q2 2023 Jul 28, 2023	SELL	$4.79 - $8.3 $770,768 - $1.34 Million	-160,912 Reduced 3.07%	5,081,168 $30.1 Million
Q1 2023 May 03, 2023	BUY	$5.3 - $10.93 $1.72 Million - $3.54 Million	323,785 Added 6.58%	5,242,080 $27.8 Million

Q4 2022 Jan 24, 2023	BUY	$4.1 - $8.94 $161,371 - $351,869	39,359 Added 0.81%	4,918,295 $26.2 Million
Q3 2022 Oct 27, 2022	BUY	$7.27 - $12.92 $50,126 - $89,083	6,895 Added 0.14%	4,878,936 $40.1 Million
Q2 2022 Aug 08, 2022	BUY	$6.92 - $15.97 $5.93 Million - $13.7 Million	856,706 Added 21.34%	4,872,041 $53.1 Million
Q1 2022 May 05, 2022	SELL	$11.52 - $22.05 $342,800 - $656,141	-29,757 Reduced 0.74%	4,015,335 $57.8 Million
Q4 2021 Jan 20, 2022	BUY	$17.63 - $27.1 $71.3 Million - $110 Million	4,045,092 New	4,045,092 $79.9 Million

Others Institutions Holding EXAI

# of Institutions

Shares Held

38.6M

Call Options Held

99.7K

Put Options Held

191K

View Full List

About Exscientia plc

Ticker EXAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,461,000
Market Cap $625M
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...

More about EXAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Exscientia PLC Transaction History